Search results
Author(s):
Riccardo Cappato
,
Rui Providencia
Added:
1 year ago
What updates do ECAS recommend for catheter ablation of atrial fibrillation?In this short interview, Prof Riccardo Cappato (IRCCS Humanitas Research Hospital, Milan, IT) and Prof Rui Providência (St Bartholomew's Hospital, London, UK) discuss new guidelines released by ECAS on catheter ablation for atrial fibrillation (AF). Prof Cappato and Prof Providência explain the need for an updated and…
View more
Author(s):
Renato D Lopes
Added:
1 year ago
ESC Congress 24 — AF screening with a wearable ECG device increases diagnosis by over 50% but did not significantly reduce hospitalisation rates for stroke.We are joined onsite at ESC Congress 2024 by Dr Renato Lopes (Duke University Medical Center, NC) to discuss the findings from the GUARD-AF Trial (NCT04126486, Bristol-Myers Squibb), which was designed to determine if screening for undiagnosed…
View more
Author(s):
Manesh R Patel
,
Harriette Van Spall
Added:
1 year ago
ESC Congress 2024 — OCEANIC-AF was halted early due to a lack of efficacy in 2023. Investigators shared details of the trial at ESC, comparing asundexian against apixaban in patients with atrial fibrillation at risk of stroke.Host Dr Harriette Van Spall (McMaster University, Hamilton, Canada) sits down with primary investigator Dr Manesh R Patel (Duke University Health System, USA) to discuss the…
View more
Medical Therapy of Heart Failure and AF
Author(s):
Gregory Burkman
,
Gerald V Naccarelli
Added:
1 week ago
Review Article
Author(s):
Isabel Deisenhofer
Added:
1 year ago
HRS 2024 — Prof Isabel Deisenhofer (German Heart Center Munich, Technical University of Munich, DE), investigator, joins us to discuss the findings from the TAILORED-AF trial (NCT04702451, Volta Medical).This randomised controlled trial compared a tailored ablation strategy targeting areas of patio-temporal dispersion in combination with pulmonary vein isolation (PVI) to anatomical ablation…
View more
Author(s):
Kenneth Bilchick
Added:
1 week ago
HRS Congress 2026 — Dr Kenneth Bilchick (UVA Heart & Vascular Center, Charlottesville, VA, US) joins us to discuss findings from a study examining whether the protective effect of glucagon-like peptide-1 (GLP-1) receptor agonists on atrial fibrillation risk operates independently of weight loss and survival.Interview Questions:What is the current understanding of how GLP-1 receptor agonists may…
View more
Atrial Cardiomyopathy and AF in Heart Failure Substrates
Author(s):
Bharat K Kantharia
,
Lingling Wu
,
Mohit M Hulsurkar
,
et al
Added:
2 months ago
Review Article
Defining AF Cardiomyopathy
Author(s):
Nikhil Ahluwalia
,
Shohreh Honarbakhsh
,
Ross Hunter
,
et al
Added:
2 months ago
Review Article
The Global Impact of AF
Author(s):
Maham F Karatela
,
Hugh Calkins
Added:
6 months ago
Review Article